RxDoctor Payments Data

Emily Campbell, PA

Physician Assistant · Winston Salem, NCNPI 1275259541

Payments from drug & device makers

$1,246in general payments, 2019–2025

Across 12 payments — averaging $103.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$389
  • Bayer$209
  • Cequr Corporation$137
  • Amgen$125
  • Abbott$111
  • Novo Nordisk$90
  • plus $185 from 3 others

What the payments were for

  • Travel & lodging$121%
  • Food & beverage$1,23499%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,246 in reported general payments places this provider in the 70th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$9,405
Medicare patients
73
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$124,241
MounjaroTirzepatide75$84,617
JardianceEmpagliflozin46$41,877
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog63$33,171
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/715$28,635
RybelsusSemaglutide20$20,831
TrulicityDulaglutide11$12,729
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$12,546
Humalog Kwikpen U-100Insulin Lispro31$9,839
NovologInsulin Aspart18$6,979
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$6,577
Novolog FlexpenInsulin Aspart31$4,618
Nano 2nd Gen Pen NeedlePen Needle, Diabetic37$4,483
Insulin Lispro Kwikpen U-100Insulin Lispro15$3,907
HumalogInsulin Lispro11$2,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$90$152,050127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →